Literature DB >> 12529749

Rescue of prothrombin-deficiency by transgene expression in mice.

William Y Sun1, Mallory J Coleman, David P Witte, Sandra J F Degen.   

Abstract

Prothrombin has diverse biological functions in addition to its well established role in blood coagulation. In order to study these functions in more detail mouse model systems are needed. Since deficiency of prothrombin in mice results in partial embryonic lethality and neonatal death, alternative approaches are required to study the biology of prothrombin in the adult mouse. The liver is the major site of synthesis of prothrombin and therefore liver-specific promoters were used to express prothrombin in transgenic mice. Mice generated from crosses with these transgenic mice and mice hemizygous for the knock-out allele were used to test whether liver-specific expression is sufficient to correct the phenotype of null mice and whether liver-specific expression is sufficient for the development and survival of mice to adulthood. The mouse albumin promoter/enhancer was used initially for transgene expression without success in obtaining transgene positive, endogenous prothrombin null mice. Two lines of transgene positive, endogenous prothrombin deficient mice were obtained using the mouse transthyretin (TTR) promoter/enhancer driving expression of a human prothrombin cDNA. One line was able to rescue both the embryonic and the neonatal lethality while the other line was only able to correct the embryonic lethality. Expression of prothrombin was restricted to the liver and stomach in one line and to the liver, pancreas, stomach and kidney in the other line of mice. Thrombin activity for one line was determined to be at 5-10% of wildtype levels. These mice developed normally and did not have spontaneous bleeding events unless traumatized. Therefore, transgenic expression of human prothrombin is sufficient for the rescue of the lethality found for prothrombin deficiency in mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12529749

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation.

Authors:  Qiulan Ding; Likui Yang; Xiaoqing Zhao; Wenman Wu; Xuefeng Wang; Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2016-12-15       Impact factor: 5.249

2.  A combined deficiency of tissue factor and PAR-4 is associated with fatal pulmonary hemorrhage in mice.

Authors:  Michael F Bode; Nigel Mackman
Journal:  Thromb Res       Date:  2016-08-22       Impact factor: 3.944

3.  Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms.

Authors:  Joseph S Palumbo; Kathryn E Talmage; Jessica V Massari; Christine M La Jeunesse; Matthew J Flick; Keith W Kombrinck; Zhiwei Hu; Kelley A Barney; Jay L Degen
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

4.  Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.

Authors:  Paritha I Arumugam; Eric S Mullins; Shiva Kumar Shanmukhappa; Brett P Monia; Anastacia Loberg; Maureen A Shaw; Tilat Rizvi; Janaka Wansapura; Jay L Degen; Punam Malik
Journal:  Blood       Date:  2015-08-18       Impact factor: 22.113

5.  Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain.

Authors:  Eric S Mullins; Keith W Kombrinck; Kathryn E Talmage; Maureen A Shaw; David P Witte; Joni M Ullman; Sandra J Degen; William Sun; Matthew J Flick; Jay L Degen
Journal:  Blood       Date:  2008-10-16       Impact factor: 22.113

Review 6.  Mouse models of hemostasis.

Authors:  Bassem M Mohammed; Dougald M Monroe; David Gailani
Journal:  Platelets       Date:  2020-01-28       Impact factor: 3.862

Review 7.  Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond.

Authors:  Sven Danckwardt; Matthias W Hentze; Andreas E Kulozik
Journal:  J Mol Med (Berl)       Date:  2013-08-17       Impact factor: 4.599

8.  A Novel Heterozygous Variant in F2 Gene in a Chinese Patient With Coronary Thrombosis and Acute Myocardial Infarction Leads to Antithrombin Resistance.

Authors:  Yi Tang; Liyang Zhang; Wenlin Xie; Jieyuan Jin; Yujiao Luo; Mingyang Deng; Zhengyu Liu; Hong Wei Pan; Yi Zhang; Zhaofen Zheng; Liang-Liang Fan
Journal:  Front Genet       Date:  2020-03-03       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.